Want to join the conversation?
$VRTX expects to provide net product revenue guidance for Orkambi during 2016. As of Dec. 31, more than 4,500 people had begun treatment in the U.S. since approval. $VRTX sees vast majority of eligible patients in the U.S. will begin treatment by end of 2016. $VRTX will recognize revenues from Orkambi sales in the U.S. and Germany in 2016.
$WBA is yet to receive US anti-trust clearance for its Rite Aid acquisition. The deadline for the deal expires on January 27.
$BMY plunge 7.2%. No credits to the non-acceleration of approval for lung cancer combination treatment.
Well this is big! I don’t know if it’s someone’s monopoly or genuine excitement, but either way, $CSX is up 23% after market closed. I heard some activist investor is going to blow big money into CSX Corp. Anyone mind explaining?